SCHEMBL163620

SCHEMBL163620

O=C(O)c1cc(O)co1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL160899 0.78
SCHEMBL183475 0.78
SCHEMBL27769296 0.78
Hydrochloric Acid SCHEMBL11782854 0.76 KMT2A (0.50)
SCHEMBL26907933 0.75 NR4A2 (0.43)
SCHEMBL69933 0.75 NR4A2 (0.43)
SCHEMBL163619 0.75
SCHEMBL1171093 0.75 DAO (0.50)
SCHEMBL4731439 0.73
Hydrochloric Acid SCHEMBL28355104 0.73 NR4A2 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7297168-B2 Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof THE PROCTER & GAMBLE COMPANY (US) 2007-11-20 US claimed
US-20050198745-A1 Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof PROCTER & GAMBLE COMPANY, THE 2005-09-15 US claimed
CN-108383838-B Amide derivative and application thereof in hypertension, hyperlipidemia and atherosclerosis 浙江药苑生物科技有限公司 2020-08-28 CN disclosed
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
EP-2315651-B1 USE OF MEDIATORS IN THE MANUFACTURING OF FIBERBOARDS UNIV GOETTINGEN GEORG AUGUST (DE) 2014-02-26 EP disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed
US-20110118458-A1 USE OF MEDIATORS IN THE PRODUCTION OF FIBERBOARDS GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS (DE) 2011-05-19 US disclosed
EP-2315651-A2 USE OF MEDIATORS IN THE PRODUCTION OF FIBREBOARD Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts (DE) 2011-05-04 EP disclosed
US-20060122232-A1 4-Hydroxyfuroic acid derivatives DEVELOPMENT CENTER FOR BIOTECHNOLOGY 2006-06-08 US disclosed
US-20050198745-A1 Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof PROCTER & GAMBLE COMPANY, THE 2005-09-15 US disclosed
WO-2005074875-A2 KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF THE PROCTER & GAMBLE COMPANY (US) 2005-08-18 WO disclosed
US-6596760-B1 Substituted 4-hydroxy-2-furoic acids are obtained by the fermentation of an asterriquinone, which is a natural product having a 2,5-dioxy-3,6-bis(indolyl)quinone structure. The compounds modulate insulin receptor tyrosine kinase activity MERCK & CO. INC. 2003-07-22 US disclosed
US-6596760-B1 Substituted 4-hydroxy-2-furoic acids are obtained by the fermentation of an asterriquinone, which is a natural product having a 2,5-dioxy-3,6-bis(indolyl)quinone structure. The compounds modulate insulin receptor tyrosine kinase activity MERCK & CO. INC. 2003-07-22 US disclosed
US-6596760-B1 Substituted 4-hydroxy-2-furoic acids are obtained by the fermentation of an asterriquinone, which is a natural product having a 2,5-dioxy-3,6-bis(indolyl)quinone structure. The compounds modulate insulin receptor tyrosine kinase activity MERCK & CO. INC. 2003-07-22 US disclosed
US-20030134890-A1 Antidiabetic 4-hydroxy-2-furoic acids MERCK & CO., INC. 2003-07-17 US disclosed
US-20030134890-A1 Antidiabetic 4-hydroxy-2-furoic acids MERCK & CO., INC. 2003-07-17 US disclosed
US-20030134890-A1 Antidiabetic 4-hydroxy-2-furoic acids MERCK & CO., INC. 2003-07-17 US disclosed